CN102718695A - Method for synthesizing aza-bicyclo octane [3.3.0] derivatives - Google Patents

Method for synthesizing aza-bicyclo octane [3.3.0] derivatives Download PDF

Info

Publication number
CN102718695A
CN102718695A CN2012102118757A CN201210211875A CN102718695A CN 102718695 A CN102718695 A CN 102718695A CN 2012102118757 A CN2012102118757 A CN 2012102118757A CN 201210211875 A CN201210211875 A CN 201210211875A CN 102718695 A CN102718695 A CN 102718695A
Authority
CN
China
Prior art keywords
reaction
formula
compound
synthetic
tms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012102118757A
Other languages
Chinese (zh)
Other versions
CN102718695B (en
Inventor
姜雪峰
谭忠飞
姜卫华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China Normal University
Original Assignee
East China Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China Normal University filed Critical East China Normal University
Priority to CN201210211875.7A priority Critical patent/CN102718695B/en
Publication of CN102718695A publication Critical patent/CN102718695A/en
Application granted granted Critical
Publication of CN102718695B publication Critical patent/CN102718695B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a method for synthesizing aza-bicyclo octane [3.3.0] derivatives shown as a formula (I). 1,2,3,6-tetrahydrophthalimide (V) is used as an initial raw material; and the aza-bicyclo octane [3.3.0] derivatives shown as the formula (I) are obtained by protective group addition, reduction reaction, protective group removing reaction, oxidation reaction and cyclization decarboxylation reaction sequentially. The method is mild in reaction conditions, readily available and cheap in raw materials, simple in synthetic route and high in yield; and the aza-bicyclo octane [3.3.0] derivatives serving as important medicinal intermediates are widely applied to industrialized large-scale production.

Description

一种氮杂双环[3.3.0]辛烷衍生物的合成方法A kind of synthetic method of azabicyclo[3.3.0]octane derivative

技术领域 technical field

本发明属于有机化合物工艺应用技术领域,具体涉及一种氮杂双环[3.3.0]辛烷衍生物的合成方法。The invention belongs to the technical field of organic compound technology application, and specifically relates to a synthesis method of azabicyclo[3.3.0]octane derivatives.

背景技术 Background technique

氮杂双环[3.3.0]辛烷衍生物(aza-bicyclo octane[3.3.0]derivatives)是一类非常重要的化工中间体,具有非常高的医药应用价值。在最近几年的报道的一些新药物中,如治疗糖尿病用丝氨酸蛋白酶二肽肽酶(DDP-4)抑制剂(Bioorganic and Medicinal Chemistry Letters,2010,20,3565-3568),是具有氮杂双环[3.3.0]辛烷结构。现有技术中氮杂双环[3.3.0]辛烷衍生物的合成方法的主要包括:方法之一如方程式(a)所示,是将(7S,8R)-1,4-dioxaspiro[4.4]nonane-7,8-dicarboxylic acid dimethyl ester与二级胺于190℃下封管反应16小时得到(J.Org.Chem.1989,54,5115-5122和WO 2004/087142)。该方法条件苛刻,在工业放大规模化生产中难以实现。另一种方法是以dimethyl 2-allyl-2-(prop-2-ynyl)malonate在金属催化下通过Pauson-Khand反应成环,然后还原烯键得到,如方程式(b)所示(OrganicLetters,2002,4,3983-3988,J.Org.Chem.2002,67,1233-246和US 2004/44029),该方法是以剧毒的金属试剂Co2(CO)8为催化剂,有潜在的危险性。Aza-bicyclo octane [3.3.0] derivatives (aza-bicyclo octane [3.3.0] derivatives) is a very important class of chemical intermediates, with very high pharmaceutical application value. In some new drugs reported in recent years, such as serine protease dipeptidase peptidase (DDP-4) inhibitors for the treatment of diabetes (Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3565-3568), are azabicyclic [3.3.0] Octane structure. The synthetic methods of azabicyclo[3.3.0]octane derivatives in the prior art mainly include: one of the methods, as shown in equation (a), is to combine (7S,8R)-1,4-dioxaspiro[4.4] Nonane-7,8-dicarboxylic acid dimethyl ester reacted with a secondary amine at 190°C for 16 hours with locking (J.Org.Chem.1989, 54, 5115-5122 and WO 2004/087142). The method has harsh conditions and is difficult to realize in industrial scale-up production. Another method is to obtain dimethyl 2-allyl-2-(prop-2-ynyl)malonate through the Pauson-Khand reaction under metal catalysis, and then reduce the olefinic bond, as shown in equation (b) (OrganicLetters, 2002 , 4,3983-3988, J.Org.Chem.2002,67, 1233-246 and US 2004/44029), the method is to be a catalyst with highly toxic metal reagent Co 2 (CO) 8 , which is potentially dangerous .

Figure BDA00001806468200011
Figure BDA00001806468200011

发明内容 Contents of the invention

本发明克服现有技术上述缺陷,提出一种产率高、操作简单,适于工业化规模生产的式(I)化合物氮杂双环[3.3.0]辛烷衍生物(aza-bicyclo octane[3.3.0]derivatives)的合成方法。The present invention overcomes the above-mentioned defects of the prior art, proposes a compound azabicyclo [3.3.0] octane derivative (aza-bicyclo octane [3.3. 0] derivatives) synthetic method.

本发明提出的一种氮杂双环[3.3.0]辛烷衍生物的合成方法,是以式(V)化合物1,2,3,6-四氢邻苯二酰亚胺为原料,依次经过上保护基、还原反应、脱保护基反应、氧化反应、环化脱羧反应,得到所述如式(I)的氮杂双环[3.3.0]辛烷衍生物;A kind of synthetic method of azabicyclo[3.3.0]octane derivatives proposed by the present invention is to use the compound 1,2,3,6-tetrahydrophthalimide of formula (V) as raw material, through Protecting group, reduction reaction, deprotection group reaction, oxidation reaction, cyclodecarboxylation reaction to obtain the azabicyclo[3.3.0]octane derivative as described in formula (I);

Figure BDA00001806468200021
Figure BDA00001806468200021

其反应路线为:Its reaction route is:

Figure BDA00001806468200022
Figure BDA00001806468200022

其中,in,

当A是O时,R是C1~C8的烷基取代基、或芳基;When A is O, R is an alkyl substituent of C 1 to C 8 or an aryl group;

当A是N时,R是氢、C1~C8烷基、或芳基;When A is N, R is hydrogen, C 1 -C 8 alkyl, or aryl;

PG是Ph3C、叔丁基、MOM、BOM、TMS、萘甲基、

Figure BDA00001806468200023
其中,X是H、F、Cl、Br、I、NO2、CH3、CH3CH2、OCH3、或OCH3CH2。PG is Ph 3 C, tert-butyl, MOM, BOM, TMS, naphthylmethyl,
Figure BDA00001806468200023
Wherein, X is H, F, Cl, Br, I, NO 2 , CH 3 , CH 3 CH 2 , OCH 3 , or OCH 3 CH 2 .

其中,所述上保护基反应是以式(V)化合物1,2,3,6-四氢邻苯二甲酰亚胺为原料,在碱性条件下的卤代保护基反应,生成式(IV)化合物。Wherein, the protecting group reaction is based on formula (V) compound 1,2,3,6-tetrahydrophthalimide as a raw material, and the halogenated protecting group reaction under alkaline conditions generates the formula ( IV) Compounds.

所述上保护基反应中所用的碱是K2CO3,KHCO3,KOH,KOMe,KOEt,KOtBu,KOPr,KOiPr,Na2CO3,NaHCO3,NaOH,NaOMe,NaOEt,NaOPr,NaOiPr,NaH,KH,CaH2,吡啶,三乙胺或二异丙基乙基胺。The base used in the protecting group reaction is K 2 CO 3 , KHCO 3 , KOH, KOMe, KOEt, KO t Bu, KOPr, KO i Pr, Na 2 CO 3 , NaHCO 3 , NaOH, NaOMe, NaOEt, NaOPr , NaO i Pr, NaH, KH, CaH 2 , pyridine, triethylamine or diisopropylethylamine.

其中,所述还原反应是在非质子溶剂中以还原剂将式(IV)化合物的酰亚胺上得羰基还原为亚甲基,生成式(III)化合物。Wherein, the reduction reaction is to reduce the carbonyl on the imide of the compound of formula (IV) to methylene with a reducing agent in an aprotic solvent to generate the compound of formula (III).

所述非质子溶剂是四氢呋喃,甲基四氢呋喃,乙醚,甲基叔丁基醚,苯,甲苯或乙苯。The aprotic solvent is tetrahydrofuran, methyl tetrahydrofuran, diethyl ether, methyl tert-butyl ether, benzene, toluene or ethylbenzene.

所述还原剂为LiAlH4The reducing agent is LiAlH 4 .

式(III)化合物经过所述脱保护基反应生成式(II)化合物,这一反应过程的高收率是本发明的决定因素之一。The compound of formula (III) generates the compound of formula (II) through the deprotection reaction, and the high yield of this reaction process is one of the decisive factors of the present invention.

其中,当PG是Ph3C、叔丁基、甲基甲醚基(MOM)、苄基甲醚基(BOM)、三甲基硅基(TMS)或萘甲基时,所述脱保护基反应是将式(III)化合物在酸性或者碱性条件下先脱去保护基变成二级胺,再在碱性条件下与卤代甲酸酯或卤代甲酰胺反应,生成式(II)的化合物。Wherein, when PG is Ph 3 C, tert-butyl, methyl methyl ether (MOM), benzyl methyl ether (BOM), trimethylsilyl (TMS) or naphthyl methyl, the deprotection group The reaction is to remove the protective group of the compound of formula (III) under acidic or basic conditions to become a secondary amine, and then react with haloformic acid ester or haloformamide under basic conditions to generate formula (II) compound of.

式(III)化合物中,五元环N原子接个常见的保护基团(PG),在酸性或者碱性的条件下脱去保护基,然后在N原子上连上含酯基或酰胺基的保护基,从而在构建另外一个五元环时不会破坏此五元环。In the compound of formula (III), the N atom of the five-membered ring is connected with a common protecting group (PG), and the protecting group is removed under acidic or basic conditions, and then the N atom is connected with an ester group or amide group. Protecting group, thereby can not destroy this five-membered ring when constructing another five-membered ring.

所述脱保护基反应中所用的碱为NaOH,KOH,Na2CO3,K2CO3,NaHCO3或KHCO3The base used in the deprotection reaction is NaOH, KOH, Na 2 CO 3 , K 2 CO 3 , NaHCO 3 or KHCO 3 .

所述脱保护基反应所用的酸为HCl,HBr,H2SO4,H3PO4,AcOH,CF3COOH或TsOH。The acid used in the deprotection reaction is HCl, HBr, H 2 SO 4 , H 3 PO 4 , AcOH, CF 3 COOH or TsOH.

其中,当PG是所述脱保护剂反应是将式(III)化合物先在催化剂碱的催化下与光气或三光气反应,再与相应的醇或胺反应,生成式(II)化合物;其中,X是H、F、Cl、Br、I、NO2、CH3、CH3CH2、OCH3、或OCH3CH2where, when PG is The deprotecting agent reaction is to react the compound of formula (III) with phosgene or triphosgene under the catalysis of catalyst base, and then react with corresponding alcohol or amine to generate the compound of formula (II); wherein, X is H, F, Cl, Br, I, NO2 , CH3 , CH3CH2 , OCH3 , or OCH3CH2 .

当PG是

Figure BDA00001806468200032
时,式(III)化合物的结构如式(III')所示。式(III')中,X是H、F、Cl、Br、I、NO2、CH3、CH3CH2、OCH3、或OCH3CH2。式(III')化合物在催化剂碱的催化下与光气或三光气反应,生成结构如式(III″)所示的酰氯化合物,再与相应的醇或胺反应,得到式(II)化合物。此反应是一锅法合成,不需要分离中间产物,这样可以避免操作带来的损失,提高效率及产率,节省成本。when PG is
Figure BDA00001806468200032
, the structure of the compound of formula (III) is shown in formula (III'). In formula (III'), X is H, F, Cl, Br, I, NO 2 , CH 3 , CH 3 CH 2 , OCH 3 , or OCH 3 CH 2 . The compound of formula (III') reacts with phosgene or triphosgene under the catalysis of the catalyst base to generate an acid chloride compound with the structure shown in formula (III"), and then reacts with the corresponding alcohol or amine to obtain the compound of formula (II). This reaction is a one-pot synthesis without the need to separate intermediate products, which can avoid losses caused by operations, improve efficiency and yield, and save costs.

Figure BDA00001806468200033
Figure BDA00001806468200033

所述的催化剂碱是三乙胺,三甲胺,二异丙基乙基胺,二乙胺,二丙胺,二丁胺,吡啶或DMAP之任意一种。The catalyst base is any one of triethylamine, trimethylamine, diisopropylethylamine, diethylamine, dipropylamine, dibutylamine, pyridine or DMAP.

其中,所述氧化反应是将式(II)化合物经氧化剂氧化成二羧酸结构;优选地,所述氧化剂是强氧化剂。优选地,所述氧化剂是H2O2,O3,KMnO4或K2Cr2O7Wherein, the oxidation reaction is to oxidize the compound of formula (II) into a dicarboxylic acid structure through an oxidizing agent; preferably, the oxidizing agent is a strong oxidizing agent. Preferably, the oxidizing agent is H 2 O 2 , O 3 , KMnO 4 or K 2 Cr 2 O 7 .

其中,所述环化脱羧反应是在所述氧化反应之后进行,是在酸性溶剂中环化脱羧生成式(I)化合物;其中,所述酸性溶剂为乙酸、乙酸酐或丙酸。Wherein, the cyclodecarboxylation reaction is carried out after the oxidation reaction, and the compound of formula (I) is generated by cyclodecarboxylation in an acidic solvent; wherein, the acidic solvent is acetic acid, acetic anhydride or propionic acid.

本发明的反应路线,如下所示:The reaction scheme of the present invention is as follows:

Figure BDA00001806468200041
Figure BDA00001806468200041

本发明合成方法的条件温和,原料易得价廉,合成路线简单,产率较高,产物式(I)化合物作为重要的一类医药中间体,广泛适用于工业化规模生产。本发明合成方法通过上保护基保护,提高整个路线关键反应(还原反应,成本最高)的收率,除掉杂质简单,节省成本。而就最终产物的产率而言没有伴随损耗,反而提高。The synthesis method of the invention has mild conditions, readily available and cheap raw materials, simple synthesis route and high yield, and the compound of the product formula (I), as an important class of pharmaceutical intermediates, is widely applicable to industrial scale production. The synthetic method of the present invention improves the yield of the key reaction (reduction reaction, the highest cost) of the whole route through the protection of the protecting group, and the removal of impurities is simple and the cost is saved. In terms of the yield of the final product, there is no concomitant loss, but an increase.

具体实施方式 Detailed ways

结合以下具体实施例,对本发明作进一步的详细说明,本发明的保护内容不局限于以下实施例。在不背离发明构思的精神和范围下,本领域技术人员能够想到的变化和优点都被包括在本发明中,并且以所附的权利要求书为保护范围。实施本发明的过程、条件、试剂、实验方法等,除以下专门提及的内容之外,均为本领域的普遍知识和公知常识,本发明没有特别限制内容。以下实施例所给出的数据包括具体操作和反应条件及产物。产物纯度通过核磁鉴定。In conjunction with the following specific examples, the present invention will be further described in detail, and the protection content of the present invention is not limited to the following examples. Without departing from the spirit and scope of the inventive concept, changes and advantages conceivable by those skilled in the art are all included in the present invention, and the appended claims are the protection scope. The process, conditions, reagents, experimental methods, etc. for implementing the present invention are general knowledge and common knowledge in the art except for the content specifically mentioned below, and the present invention has no special limitation content. The data given in the following examples include specific operating and reaction conditions and products. The purity of the product was identified by NMR.

实施例1Example 1

Figure BDA00001806468200051
Figure BDA00001806468200051

称取1,2,3,6-四氢邻苯二甲酰亚胺V(4540.0mg,30.0mmol),K2CO3(12440.0mg,90.0mmol),TBAB(970.0mg,3.0mmol)于250mL圆底烧瓶内,加入50.0mL DMF溶解。称取氯化苄(4940.0mg,39.0mmol),搅拌下缓慢的滴加到反应瓶内。5h后反应完毕,加入50.0mL水淬灭反应。然后加入100.0mL乙酸乙酯萃取,分液后有机相用饱和食盐水洗涤(40.0mL×5),用无水硫酸钠干燥过夜。过滤除去硫酸钠,旋转蒸发除去乙酸乙酯,得到白色固体粗产品。用乙酸乙酯/正己烷重结晶得到5740.0mg目标化合物,收率79.3%。质谱分析MS(ESI,m/s):241。Weigh 1,2,3,6-tetrahydrophthalimide V (4540.0mg, 30.0mmol), K 2 CO 3 (12440.0mg, 90.0mmol), TBAB (970.0mg, 3.0mmol) in 250mL In the round bottom flask, add 50.0mL DMF to dissolve. Benzyl chloride (4940.0mg, 39.0mmol) was weighed and slowly added dropwise into the reaction flask with stirring. After 5 h, the reaction was completed, and 50.0 mL of water was added to quench the reaction. Then 100.0 mL of ethyl acetate was added for extraction, and after separation, the organic phase was washed with saturated brine (40.0 mL×5), and dried over anhydrous sodium sulfate overnight. Sodium sulfate was removed by filtration, and ethyl acetate was removed by rotary evaporation to obtain the crude product as a white solid. Recrystallization from ethyl acetate/n-hexane gave 5740.0 mg of the target compound, with a yield of 79.3%. Mass spectrometry MS (ESI, m/s): 241.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.30~7.27(m,5H),5.88~5.87(t,2H),4.62(s,2H),3.10~3.08(t,2H),2.63~2.58(m,2H),2.25~2.19(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.30~7.27(m,5H),5.88~5.87(t,2H),4.62(s,2H),3.10~3.08(t,2H) ,2.63~2.58(m,2H),2.25~2.19(m,2H).

实施例2Example 2

操作同实例1。产率:81.3%,白色固体。质谱分析MS(ESI,m/s):393。The operation is the same as example 1. Yield: 81.3%, white solid. Mass spectrometry MS (ESI, m/s): 393.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.29~7.04(m,15H),5.84~5.83(t,2H),2.96~2.94(m,2H),2.50~2.46(m,2H),2.11~2.06(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.29~7.04(m,15H),5.84~5.83(t,2H),2.96~2.94(m,2H),2.50~2.46(m, 2H), 2.11~2.06(m, 2H).

实施例3Example 3

Figure BDA00001806468200061
Figure BDA00001806468200061

称取含量60%NaH(96.0mg)于50mL圆底烧瓶内,加入新蒸的THF。称取1,2,3,6-四氢邻苯二甲酰亚胺V(302.3mg)溶解于5.0mL THF中缓慢到反应瓶内,直到没有气泡产生。将MOMCl(193.0mg)缓慢的滴加到上述反应液里面后,加入KI(32.2mg),搅拌反应3h完毕。加入水淬灭反应。然后加入乙酸乙酯萃取,分液后有机相用饱和食盐水洗涤,用无水硫酸钠干燥。得到无色液体粗产品,柱层析得到321.3mg目标化合物,收率82.3%。质谱分析MS(ESI,m/s)196(M+H)。Weigh 60% NaH (96.0mg) into a 50mL round bottom flask and add freshly steamed THF. Weigh 1,2,3,6-tetrahydrophthalimide V (302.3mg) and dissolve it in 5.0mL THF slowly into the reaction flask until no bubbles are generated. After MOMCl (193.0mg) was slowly added dropwise into the above reaction solution, KI (32.2mg) was added, and the reaction was stirred for 3h to complete. Water was added to quench the reaction. Then ethyl acetate was added for extraction, and after liquid separation, the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The crude product was obtained as a colorless liquid, and 321.3 mg of the target compound was obtained by column chromatography, with a yield of 82.3%. Mass spectrometry MS (ESI, m/s) 196 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.92~5.90(t,2H),4.84(s,2H),3.29(s,2H),3.14~3.13(t,2H),2.66~2.61(m,2H),2.27~2.21(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.92~5.90(t,2H),4.84(s,2H),3.29(s,2H),3.14~3.13(t,2H),2.66 ~2.61(m,2H), 2.27~2.21(m,2H).

实施例4Example 4

Figure BDA00001806468200062
Figure BDA00001806468200062

称取LiAlH4(380.0mg)于100mL带回流冷凝管的双口瓶内,抽空换氮气,加入20.0mLTHF。称取化合物IV(a)(1206.5mg)用15.0mL THF溶解,缓慢滴加到双口瓶内。滴加完毕后,加热回流,TLC检测原料基本消失。冷却到室温,用水淬灭反应,然后再加入THF稀释,用无水硫酸钠干燥。得到无色油状粗产品。产物足够纯,无需纯化直接投入下步反应。质谱分析MS(ESI,m/s):214(M+H)。Weigh LiAlH 4 (380.0mg) into a 100mL two-necked flask with a reflux condenser, evacuate for nitrogen, and add 20.0mLTHF. Weigh compound IV(a) (1206.5mg) and dissolve it in 15.0mL THF, and slowly drop it into the two-necked bottle. After the dropwise addition was completed, it was heated to reflux, and the raw material basically disappeared as detected by TLC. After cooling to room temperature, the reaction was quenched with water, then diluted with THF, and dried over anhydrous sodium sulfate. The crude product was obtained as a colorless oil. The product was pure enough to be put directly into the next reaction without purification. Mass spectrometry MS (ESI, m/s): 214 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.31~7.19(m,5H),5.81~5.80(t,2H),3.60(s,2H),2.93~2.89(m,2H),2.38~2.37(m,2H),2.20~2.11(m,4H),1.87~1.83(d,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.31~7.19(m,5H),5.81~5.80(t,2H),3.60(s,2H),2.93~2.89(m,2H) ,2.38~2.37(m,2H),2.20~2.11(m,4H),1.87~1.83(d,2H).

实施例5Example 5

Figure BDA00001806468200071
Figure BDA00001806468200071

操作同实例4。产率:72.3%,白色固体。质谱分析MS(ESI,m/s):365。The operation is the same as example 4. Yield: 72.3%, white solid. Mass spectrometry MS (ESI, m/s): 365.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.37~7.10(m,15H),5.52~5.46(t,2H),3.46~2.45(m,2H),2.79~2.70(m,2H),2.23~2.10(m,4H),2.05~1.97(m,2H),1.86~1.79(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.37~7.10(m,15H),5.52~5.46(t,2H),3.46~2.45(m,2H),2.79~2.70(m, 2H), 2.23~2.10(m, 4H), 2.05~1.97(m, 2H), 1.86~1.79(m, 2H).

实施例6Example 6

操作同实例4。产率:83.2%,无色油状物。质谱分析MS(ESI,m/s):138(M+H)。The operation is the same as example 4. Yield: 83.2%, colorless oil. Mass spectrometry MS (ESI, m/s): 138 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.81~5.79(t,2H),2.87~2.83(m,2H),2.41~2.37(m,2H),2.31(s,2H),2.16~2.10(m,4H),1.86~1.81(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.81~5.79(t,2H),2.87~2.83(m,2H),2.41~2.37(m,2H),2.31(s,2H) ,2.16~2.10(m,4H),1.86~1.81(m,2H).

实施例7Example 7

称取三光气(98.0mg)和DMAP(6.1mg)于反应瓶内,加入3.0mL二氯甲烷,放置冰盐浴。然后加入4.0mL化合物III′(a)的二氯甲烷溶液,滴加完毕后,与此温度下反应2h。TLC监测原料消失。快速柱层析得到99.6mg目标产品。产率:54.6%,无色油状液体。质谱分析MS(ESI,m/s):185。Weigh triphosgene (98.0 mg) and DMAP (6.1 mg) into a reaction flask, add 3.0 mL of dichloromethane, and place in an ice-salt bath. Then add 4.0 mL of compound III'(a) dichloromethane solution, after the dropwise addition, react at this temperature for 2 h. TLC monitored disappearance of starting material. Flash column chromatography yielded 99.6 mg of the title product. Yield: 54.6%, colorless oily liquid. Mass spectrometry MS (ESI, m/s): 185.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.67~5.61(t,2H),3.67~3.53(m,2H),3.37~3.28(m,2H),2.43~2.23(m,4H),1.93~1.86(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.67~5.61(t,2H),3.67~3.53(m,2H),3.37~3.28(m,2H),2.43~2.23(m, 4H), 1.93~1.86 (m, 2H).

实施例8Example 8

Figure BDA00001806468200081
Figure BDA00001806468200081

称取化合物III″(18.6mg)溶解于1.0mL二氯甲烷中加入到换好氮气的试管反应管内,将1.0mLNaOMe的甲醇溶液(浓度为0.12mol/L)缓慢滴加到反应管内,立即有无色的固体生成。5h后TLC监测原料消失,加入水淬灭反应。用二氯甲烷萃取3次,合并有机层,用无水硫酸钠干燥。得到无色油状粗产品,柱层析得到17.5mg目标化合物。产率:96.6%,无色油状液体。Weigh compound III" (18.6mg) and dissolve it in 1.0mL dichloromethane and add it to the test tube reaction tube replaced with nitrogen, slowly add 1.0mL NaOMe methanol solution (concentration is 0.12mol/L) dropwise in the reaction tube, immediately there is A colorless solid was generated. TLC monitored the disappearance of the raw material after 5h, and water was added to quench the reaction. Extracted 3 times with dichloromethane, the combined organic layer was dried with anhydrous sodium sulfate. The crude product was obtained as a colorless oil, and column chromatography gave 17.5 mg target compound. Yield: 96.6%, colorless oily liquid.

化合物II′(a)的制备也可以由化合物III′(a)制备化合物III″时反应结束时,不分离,直接加入甲醇钠的甲醇溶液反应即可得到。质谱分析MS(ESI,m/s):181。The preparation of compound II' (a) can also be prepared by compound III' (a) when the reaction ends when compound III ", without separation, can be obtained by directly adding the methanol solution of sodium methylate to react. Mass spectrometry MS (ESI, m/s ):181.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.66~5.61(t,2H),3.68(s,3H),3.49~2.39(m,2H),3.23~3.10(m,2H),2.31~2.19(m,4H),1.92~1.88(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.66~5.61(t,2H),3.68(s,3H),3.49~2.39(m,2H),3.23~3.10(m,2H) ,2.31~2.19(m,4H),1.92~1.88(m,2H).

实施例9Example 9

Figure BDA00001806468200082
Figure BDA00001806468200082

操作同实例8。产率:83.2%,无色油状物。质谱分析MS(ESI,m/s):195。The operation is the same as example 8. Yield: 83.2%, colorless oil. Mass spectrometry MS (ESI, m/s): 195.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.63~5.58(t,2H),4.10~4.07(m,2H),3.45~3.37(m,2H),3.19~3.07(m,2H),2.32~2.16(m,4H),1.89~1.84(m,2H),1.24~1.20(t,3H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.63~5.58(t,2H),4.10~4.07(m,2H),3.45~3.37(m,2H),3.19~3.07(m, 2H), 2.32~2.16(m,4H), 1.89~1.84(m,2H), 1.24~1.20(t,3H).

实施例10Example 10

Figure BDA00001806468200083
Figure BDA00001806468200083

操作同实例8。NaOBn由BnOH与NaH于THF溶液中制备得到。产率:82.3%,无色油状物。质谱分析MS(ESI,m/s):257。The operation is the same as example 8. NaOBn was prepared from BnOH and NaH in THF solution. Yield: 82.3%, colorless oil. Mass spectrometry MS (ESI, m/s): 257.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.37~7.29(m,5H),5.64(s,2H),5.16~5.09(m,2H),3.50~3.47(m,2H),3.26~3.16(m,2H),2.32~2.20(m,4H),1.93~1.88(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.37~7.29(m,5H),5.64(s,2H),5.16~5.09(m,2H),3.50~3.47(m,2H) ,3.26~3.16(m,2H),2.32~2.20(m,4H),1.93~1.88(m,2H).

实施例11Example 11

Figure BDA00001806468200091
Figure BDA00001806468200091

称取化合物III″(18.6mg)溶解于1.0mL二氯甲烷中加入到换好氮气的试管反应管内,将0.5mL 33%的二甲胺的水溶液缓慢滴加到反应管内。5h后TLC监测原料消失,加入2.0mL的水淬灭反应。用二氯甲烷萃取3次,合并有机层,用无水硫酸钠干燥,得到无色油状粗产品。柱层析得到14.6mg目标化合物II(d)。产率:75.4%,无色油状液体。Weigh compound III "(18.6mg) and dissolve it in 1.0mL dichloromethane and add it to the test tube reaction tube replaced with nitrogen, and slowly add 0.5mL 33% aqueous solution of dimethylamine dropwise to the reaction tube. After 5h, TLC monitors the raw material disappeared, adding 2.0 mL of water to quench the reaction. Extracted 3 times with dichloromethane, combined the organic layers, and dried with anhydrous sodium sulfate to obtain a colorless oily crude product. Column chromatography obtained 14.6 mg of the target compound II (d). Yield: 75.4%, colorless oily liquid.

化合物II(d)的制备也可以由化合物III′(a)制备化合物III″时反应结束时,不分离,直接加入甲醇钠的甲醇溶液反应即可得到。质谱分析MS(ESI,m/s):194。The preparation of compound II (d) can also be prepared from compound III' (a) when the reaction ends when compound III "is not separated, and can be obtained by directly adding methanol solution of sodium methoxide to react. Mass spectrometry MS (ESI, m/s) :194.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.64~5.58(t,2H),3.42~3.38(m,2H),3.16~3.12(m,2H),2.79(s,6H),2.25~2.16(m,4H),1.90~1.86(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.64~5.58(t,2H),3.42~3.38(m,2H),3.16~3.12(m,2H),2.79(s,6H) ,2.25~2.16(m,4H),1.90~1.86(m,2H).

实施例12Example 12

操作同实例11。产率:80.3%,无色油状物。质谱分析MS(ESI,m/s):223(M+H)。Operation is the same as Example 11. Yield: 80.3%, colorless oil. Mass spectrometry MS (ESI, m/s): 223 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.67~5.60(t,2H),3.43~3.39(m,2H),3.21~3.11(m,6H),2.29~2.18(m,4H),1.91~1.87(m,2H),1.12~1.09(t,6H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.67~5.60(t,2H),3.43~3.39(m,2H),3.21~3.11(m,6H),2.29~2.18(m, 4H), 1.91~1.87(m,2H), 1.12~1.09(t,6H).

实施例13Example 13

Figure BDA00001806468200093
Figure BDA00001806468200093

操作同实例11。产率:79.4%,无色油状物。质谱分析MS(ESI,m/s):278。Operation is the same as Example 11. Yield: 79.4%, colorless oil. Mass spectrometry MS (ESI, m/s): 278.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)5.66~5.59(t,2H),3.41~3.37(m,2H),3.15~3.09(m,6H),2.28~2.17(m,4H),1.90~1.86(m,2H),1.50~1.44(m,4H),1.29~1.24(m,4H),0.91~0.87(t,6H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)5.66~5.59(t,2H),3.41~3.37(m,2H),3.15~3.09(m,6H),2.28~2.17(m, 4H), 1.90~1.86(m,2H), 1.50~1.44(m,4H), 1.29~1.24(m,4H), 0.91~0.87(t,6H).

实施例14Example 14

操作同实例11。产率:65.3%,无色油状物。质谱分析MS(ESI,m/s):255(M-H)。Operation is the same as Example 11. Yield: 65.3%, colorless oil. Mass spectrometry MS (ESI, m/s): 255 (M-H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.33~7.27(m,5H),5.67~5.61(t,2H),4.44(s,2H),3.42~3.41(m,2H),3.18~3.17(m,2H),2.37~2.21(m,4H),1.94~1.89(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.33~7.27(m,5H),5.67~5.61(t,2H),4.44(s,2H),3.42~3.41(m,2H) ,3.18~3.17(m,2H),2.37~2.21(m,4H),1.94~1.89(m,2H).

实施例15Example 15

Figure BDA00001806468200102
Figure BDA00001806468200102

称取化合物V(302.3mg)于50mL带回流冷凝管的双口瓶内,抽空换氮气,加入8.0mL的三乙胺。用注射器缓慢的滴加TMSCl(434.6mg),立即有大量的固体生成。加热到90℃,反应4小时后,加入正己烷,快速过滤。将滤液旋转蒸发除去,得到450.0mg粗品。Weigh compound V (302.3mg) into a 50mL two-necked flask with a reflux condenser, evacuate for nitrogen, and add 8.0mL of triethylamine. TMSCl (434.6 mg) was slowly added dropwise with a syringe, and a large amount of solid was formed immediately. After heating to 90°C and reacting for 4 hours, n-hexane was added and filtered quickly. The filtrate was removed by rotary evaporation to give 450.0 mg of crude product.

称取LiAlH4(152.0mg,)于50.0mL的口瓶内,加入10.0mL新蒸的THF,将上步的450.0mg粗品用3.0mL THF稀释滴加到反应瓶内,滴加完毕加热使其回流反应5小时。冷却到室温,加入10.0mL THF/H2O(10:1)混合液淬灭反应,加入无水硫酸钠干燥。往滤液里面加入K2CO3(276.4mg),缓慢滴加CbzCl(375.0mg),搅拌反应2小时,反应基本结束。旋转抽干反应液,加入20.0mL水,用乙酸乙酯萃取4次,合并有机层,用无水硫酸钠干燥,柱层析得到255.0mg目标化合物II(c)。产率:49.6%。Weigh LiAlH 4 (152.0mg,) into a 50.0mL mouth bottle, add 10.0mL freshly steamed THF, dilute 450.0mg of the crude product from the previous step with 3.0mL THF and add dropwise to the reaction bottle, and heat to make it Reflux for 5 hours. Cool to room temperature, add 10.0 mL THF/H 2 O (10:1) mixture solution to quench the reaction, and add anhydrous sodium sulfate to dry. K 2 CO 3 (276.4 mg) was added to the filtrate, and CbzCl (375.0 mg) was slowly added dropwise, and the reaction was stirred for 2 hours, and the reaction was basically completed. The reaction liquid was sucked dry by rotation, 20.0 mL of water was added, extracted 4 times with ethyl acetate, the organic layers were combined, dried with anhydrous sodium sulfate, and column chromatography obtained 255.0 mg of the target compound II(c). Yield: 49.6%.

实施例16Example 16

Figure BDA00001806468200103
Figure BDA00001806468200103

称取化合物II(a)(158.7mg)和TBAB(28.0mg)于50mL的单口瓶内,加入10.0mL二氯甲烷溶解,缓慢滴加10.0mL KMnO4(415.2mg,2.63mmol)水溶液。于室温下搅拌反应2小时,TLC监测原料消失。加入1200.0mg亚硫酸钠和1.0mL浓盐酸,将反应液中得二氯甲烷旋转蒸发后,用乙酸乙酯萃取4次。合并乙酸乙酯,用无水硫酸钠干燥,得到199.2mg白色泡沫状固体粗产品。直接投入下步反应。Weigh compound II(a) (158.7mg) and TBAB (28.0mg) into a 50mL one-necked bottle, add 10.0mL dichloromethane to dissolve, and slowly add 10.0mL KMnO 4 (415.2mg, 2.63mmol) aqueous solution dropwise. The reaction was stirred at room temperature for 2 hours, and the starting material disappeared as monitored by TLC. Add 1200.0 mg of sodium sulfite and 1.0 mL of concentrated hydrochloric acid, rotate the dichloromethane obtained from the reaction liquid to evaporate, and extract 4 times with ethyl acetate. The ethyl acetates were combined and dried over anhydrous sodium sulfate to obtain 199.2 mg of the crude product as a white foamy solid. directly into the next reaction.

称取醋酸钠(107.8mg)于上述的粗产品内,加入4.0mL醋酸酐,然后再加热到120℃反应2小时反应结束。冷却到室温,加入10.0mL水,分多次加入固体碳酸钠。用二氯甲烷萃取,合并有机层,用无水硫酸钠干燥,柱层析得到108.5mg目标产品。产率:67.7%,无色油状液体。质谱分析MS(ESI,m/s):183。Weigh sodium acetate (107.8 mg) into the above crude product, add 4.0 mL of acetic anhydride, and then heat to 120° C. for 2 hours to complete the reaction. Cool to room temperature, add 10.0 mL of water, and add solid sodium carbonate several times. Extract with dichloromethane, combine the organic layers, dry over anhydrous sodium sulfate, and obtain 108.5 mg of the target product by column chromatography. Yield: 67.7%, colorless oily liquid. Mass spectrometry MS (ESI, m/s): 183.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)3.63~3.58(m,5H),3.25~3.14(m,2H),2.89~2.85(m,2H),2.46~2.39(m,2H),2.20~2.06(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)3.63~3.58(m,5H),3.25~3.14(m,2H),2.89~2.85(m,2H),2.46~2.39(m, 2H), 2.20~2.06(m,2H).

实施例17Example 17

Figure BDA00001806468200111
Figure BDA00001806468200111

操作同实例16。产率72.7%,无色油状液体。质谱分析MS(ESI,m/s):198(M+H)。Operation is the same as example 16. Yield 72.7%, colorless oily liquid. Mass spectrometry MS (ESI, m/s): 198 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)4.14~4.08(q,2H),3.72~3.64(m,2H),3.30~3.18(m,2H),2.93~2.92(m,2H),2.51~2.44(m,2H),2.17~2.11(m,2H),1.26~1.22(t,3H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)4.14~4.08(q,2H),3.72~3.64(m,2H),3.30~3.18(m,2H),2.93~2.92(m, 2H), 2.51~2.44(m,2H), 2.17~2.11(m,2H), 1.26~1.22(t,3H).

实施例18Example 18

Figure BDA00001806468200112
Figure BDA00001806468200112

操作同实施例16。产率70.0%,淡咘色固体。质谱分析MS(ESI,m/s):259。Operation is the same as in Example 16. Yield 70.0%, light-colored solid. Mass spectrometry MS (ESI, m/s): 259.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)7.37~7.30(m,5H),5.13(s,2H),3.77~3.71(m,2H),3.35~3.25(m,2H),2.96.~2.94(m,2H),2.53~2.47(m,2H),2.19~2.13(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)7.37~7.30(m,5H),5.13(s,2H),3.77~3.71(m,2H),3.35~3.25(m,2H) ,2.96.~2.94(m,2H),2.53~2.47(m,2H),2.19~2.13(m,2H).

实施例19Example 19

Figure BDA00001806468200113
Figure BDA00001806468200113

操作同实施例16。产率56.3%,无色液体。质谱分析MS(ESI,m/s):196。Operation is the same as in Example 16. Yield 56.3%, colorless liquid. Mass spectrometry MS (ESI, m/s): 196.

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)3.71~3.66(m,2H),3.28~3.23(m,2H),3.06~2.88(m,4H),2.83(s,6H),2.51~2.44(m,2H),2.19~2.13(m,2H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)3.71~3.66(m,2H),3.28~3.23(m,2H),3.06~2.88(m,4H),2.83(s,6H) ,2.51~2.44(m,2H),2.19~2.13(m,2H).

实施例20Example 20

Figure BDA00001806468200121
Figure BDA00001806468200121

操作同实施例16。产率59.0%,无色液体。质谱分析MS(ESI,m/s):225(M+H)。Operation is the same as in Example 16. Yield 59.0%, colorless liquid. Mass spectrometry MS (ESI, m/s): 225 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)3.68~3.64(d,2H),3.23~3.15(m,6H),2.94~2.85(m,2H),2.50~2.44(m,2H),2.17~2.11(m,2H),1.12~1.09(t,6H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)3.68~3.64(d,2H),3.23~3.15(m,6H),2.94~2.85(m,2H),2.50~2.44(m, 2H), 2.17~2.11(m,2H), 1.12~1.09(t,6H).

实施例21Example 21

Figure BDA00001806468200122
Figure BDA00001806468200122

操作同实施例16。产率61.6%,无色液体。质谱分析MS(ESI,m/s):281(M+H)。Operation is the same as in Example 16. Yield 61.6%, colorless liquid. Mass spectrometry MS (ESI, m/s): 281 (M+H).

1H-NMR(CDCl3/TMS,400MHz):δ(ppm)3.67~3.63(d,2H),3.23~3.20(m,2H),3.14~3.10(t,4H),2.94~2.85(m,2H),2.51~2.44(m,2H),2.17~2.11(m,2H),1.52~1.45(m,4H),1.32~1.22(m,4H),0.92~0.88(t,6H)。 1 H-NMR(CDCl 3 /TMS,400MHz):δ(ppm)3.67~3.63(d,2H),3.23~3.20(m,2H),3.14~3.10(t,4H),2.94~2.85(m, 2H), 2.51~2.44(m,2H), 2.17~2.11(m,2H), 1.52~1.45(m,4H), 1.32~1.22(m,4H), 0.92~0.88(t,6H).

Claims (12)

1.一种氮杂双环[3.3.0]辛烷衍生物的合成方法,其特征在于,以式(V)化合物1,2,3,6-四氢邻苯二甲酰亚胺为原料,依次经过上保护基、还原反应、脱保护基反应、氧化反应、环化脱羧反应,得到所述如式(I)所示的氮杂双环[3.3.0]辛烷衍生物;1. a synthetic method of azabicyclo[3.3.0]octane derivatives, characterized in that, with formula (V) compound 1,2,3,6-tetrahydrophthalimide as raw material, After successively going through protective group, reduction reaction, deprotection reaction, oxidation reaction and cyclodecarboxylation reaction, the azabicyclo[3.3.0]octane derivative as shown in formula (I) is obtained;
Figure FDA00001806468100011
Figure FDA00001806468100011
其反应路线为:Its reaction route is:
Figure FDA00001806468100012
Figure FDA00001806468100012
其中,in, 当A是O时,R是C1~C8的烷基取代基、或芳基;When A is O, R is an alkyl substituent of C 1 to C 8 or an aryl group; 当A是N时,R是氢、C1~C8烷基、或芳基;When A is N, R is hydrogen, C 1 -C 8 alkyl, or aryl; PG是Ph3C、叔丁基、MOM、BOM、TMS、萘甲基、
Figure FDA00001806468100013
其中,X是H、F、Cl、Br、I、NO2、CH3、CH3CH2、OCH3、或OCH3CH2
PG is Ph 3 C, tert-butyl, MOM, BOM, TMS, naphthylmethyl,
Figure FDA00001806468100013
Wherein, X is H, F, Cl, Br, I, NO 2 , CH 3 , CH 3 CH 2 , OCH 3 , or OCH 3 CH 2 .
2.如权利要求1所述的合成反应,其特征在于,所述上保护基反应是所述式(V)化合物经过在碱性条件下的与卤代保护基反应,生成式(IV)化合物。2. synthetic reaction as claimed in claim 1, is characterized in that, described upper protecting group reaction is that described formula (V) compound is through reacting with halogenated protecting group under alkaline condition, generates formula (IV) compound . 3.如权利要求2所述的合成反应,其特征在于,所述上保护基反应中所用的碱是K2CO3,KHCO3,KOH,KOMe,KOEt,KOtBu,KOPr,KOiPr,Na2CO3,NaHCO3,NaOH,NaOMe,NaOEt,NaOPr,NaOiPr,NaH,KH,CaH2,吡啶,三乙胺或二异丙基乙基胺。3. synthetic reaction as claimed in claim 2, it is characterized in that, the base used in the described upper protecting group reaction is K 2 CO 3 , KHCO 3 , KOH, KOMe, KOEt, KO t Bu, KOPr, KO i Pr , Na2CO3 , NaHCO3 , NaOH, NaOMe, NaOEt, NaOPr, NaOiPr , NaH, KH, CaH2 , pyridine , triethylamine or diisopropylethylamine. 4.如权利要求1所述的合成反应,其特征在于,所述还原反应是在非质子溶剂中以还原剂将式(IV)化合物的酰亚胺上得羰基还原为亚甲基,生成式(III)化合物。4. synthetic reaction as claimed in claim 1, it is characterized in that, described reduction reaction is to obtain carbonyl reduction on the imide of formula (IV) compound with reducing agent to methylene in aprotic solvent, generate formula (III) Compounds. 5.如权利要求4所述的合成反应,其特征在于,所述非质子溶剂是四氢呋喃,甲基四氢呋喃,乙醚,甲基叔丁基醚,苯,甲苯或乙苯;所述还原剂为LiAlH4。5. synthetic reaction as claimed in claim 4, is characterized in that, described aprotic solvent is tetrahydrofuran, methyl tetrahydrofuran, ether, methyl tert-butyl ether, benzene, toluene or ethylbenzene; Described reducing agent is LiAlH . 6.如权利要求1所述的合成反应,其特征在于,当PG是Ph3C、叔丁基、MOM、BOM、TMS、或萘甲基时,所述脱保护基反应是将式(III)化合物在酸性或者碱性条件下先脱去保护基变成二级胺,再在碱性条件下与卤代甲酸酯或卤代甲酰胺反应,生成式(II)的化合物。6. synthetic reaction as claimed in claim 1, it is characterized in that, when PG is Ph 3 C, tert-butyl, MOM, BOM, TMS or naphthyl methyl, described deprotection reaction is that formula (III ) compound is deprotected under acidic or basic conditions to become a secondary amine, and then reacted with haloformate or haloformamide under basic conditions to generate a compound of formula (II). 7.如权利要求6所述的合成反应,其特征在于,所述脱保护基反应所用的碱为NaOH,KOH,Na2CO3,K2CO3,NaHCO3或KHCO37. The synthesis reaction according to claim 6, wherein the base used in the deprotection reaction is NaOH, KOH, Na 2 CO 3 , K 2 CO 3 , NaHCO 3 or KHCO 3 . 8.如权利要求6所述的合成反应,其特征在于,所述脱保护基反应所用的酸为HCl,HBr,H2SO4,H3PO4,AcOH,CF3COOH或TsOH。8 . The synthesis reaction according to claim 6 , wherein the acid used in the deprotection reaction is HCl, HBr, H 2 SO 4 , H 3 PO 4 , AcOH, CF 3 COOH or TsOH. 9.如权利要求1所述的合成反应,其特征在于,当PG是
Figure FDA00001806468100021
所述脱保护基反应是将式(III)化合物先在碱的催化下与光气或三光气反应,再与相应的醇或胺反应,得到结构通式为(II)的化合物;其中,X是其中,X是H、F、Cl、Br、I、NO2、CH3、CH3CH2、OCH3、或OCH3CH2
9. synthetic reaction as claimed in claim 1, is characterized in that, when PG is
Figure FDA00001806468100021
The deprotection reaction is to react the compound of formula (III) with phosgene or triphosgene under the catalysis of the base, and then react with the corresponding alcohol or amine to obtain the compound of general structure formula (II); wherein, X is wherein X is H, F, Cl, Br, I, NO 2 , CH 3 , CH 3 CH 2 , OCH 3 , or OCH 3 CH 2 .
10.如权利要求9所述的合成反应,其特征在于,所述催化剂碱是三乙胺,三甲胺,二异丙基乙基胺,二乙胺,二丙胺,二丁胺,吡啶或DMAP之任意一种。10. synthetic reaction as claimed in claim 9, is characterized in that, described catalyst base is triethylamine, trimethylamine, diisopropyl ethylamine, diethylamine, dipropylamine, dibutylamine, pyridine or DMAP any of these. 11.如权利要求9所述的合成反应,其特征在于,所述氧化反应是将式(II)化合物经过氧化剂氧化成二羧酸;其中,所述氧化剂是H2O2,O3,KMnO4或K2Cr2O711. The synthesis reaction as claimed in claim 9, characterized in that, the oxidation reaction is that the compound of formula (II) is oxidized to dicarboxylic acid through an oxidizing agent; wherein, the oxidizing agent is H 2 O 2 , O 3 , KMnO 4 or K 2 Cr 2 O 7 . 12.如权利要求1所述的合成反应,其特征在于,所述环化脱羧反应是在酸性溶剂中环化脱羧生成式(I)化合物;其中,所述酸性溶剂为乙酸、乙酸酐或丙酸。12. synthetic reaction as claimed in claim 1, is characterized in that, described cyclodecarboxylation reaction is cyclodecarboxylation generation formula (I) compound in acidic solvent; Wherein, described acidic solvent is acetic acid, acetic anhydride or propionic acid .
CN201210211875.7A 2012-06-25 2012-06-25 Method for synthesizing aza-bicyclo octane [3.3.0] derivatives Expired - Fee Related CN102718695B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210211875.7A CN102718695B (en) 2012-06-25 2012-06-25 Method for synthesizing aza-bicyclo octane [3.3.0] derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210211875.7A CN102718695B (en) 2012-06-25 2012-06-25 Method for synthesizing aza-bicyclo octane [3.3.0] derivatives

Publications (2)

Publication Number Publication Date
CN102718695A true CN102718695A (en) 2012-10-10
CN102718695B CN102718695B (en) 2014-04-02

Family

ID=46944600

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210211875.7A Expired - Fee Related CN102718695B (en) 2012-06-25 2012-06-25 Method for synthesizing aza-bicyclo octane [3.3.0] derivatives

Country Status (1)

Country Link
CN (1) CN102718695B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1489592A (en) * 2001-02-02 2004-04-14 3,7-diazabicyclo[3,3,o] otanes and their use in treatment of cardiac arrhythmias
WO2005079496A2 (en) * 2004-02-19 2005-09-01 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
WO2007049224A1 (en) * 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
WO2007093515A1 (en) * 2006-02-15 2007-08-23 F. Hoffmann La-Roche Ag Heterocyclic antiviral compounds
CN101384596A (en) * 2006-02-15 2009-03-11 弗·哈夫曼-拉罗切有限公司 heterocyclic antiviral compounds
CN101463001A (en) * 2007-12-21 2009-06-24 上海药明康德新药开发有限公司 Octahydro cyclopenteno [c] pyrroletetrazole derivative and preparation thereof
WO2009098283A1 (en) * 2008-02-08 2009-08-13 N.V. Organon (dihydro)pyrrolo[2,1-a]isoquinolines
CN101622240A (en) * 2007-01-05 2010-01-06 第一三共株式会社 Fused substituted aminopyrrolidine derivative
CN102417475A (en) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 Azabicyclooctane derivative, preparation method and application thereof to medicine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1489592A (en) * 2001-02-02 2004-04-14 3,7-diazabicyclo[3,3,o] otanes and their use in treatment of cardiac arrhythmias
WO2005079496A2 (en) * 2004-02-19 2005-09-01 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
WO2007049224A1 (en) * 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
WO2007093515A1 (en) * 2006-02-15 2007-08-23 F. Hoffmann La-Roche Ag Heterocyclic antiviral compounds
CN101384596A (en) * 2006-02-15 2009-03-11 弗·哈夫曼-拉罗切有限公司 heterocyclic antiviral compounds
CN101622240A (en) * 2007-01-05 2010-01-06 第一三共株式会社 Fused substituted aminopyrrolidine derivative
CN101463001A (en) * 2007-12-21 2009-06-24 上海药明康德新药开发有限公司 Octahydro cyclopenteno [c] pyrroletetrazole derivative and preparation thereof
WO2009098283A1 (en) * 2008-02-08 2009-08-13 N.V. Organon (dihydro)pyrrolo[2,1-a]isoquinolines
CN102417475A (en) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 Azabicyclooctane derivative, preparation method and application thereof to medicine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RÉMY C. LEMOINE,等: "Evaluation of a 4-aminopiperidine replacement in several series of CCR5 antagonists", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
TANG PENG CHO,等: "Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
CN102718695B (en) 2014-04-02

Similar Documents

Publication Publication Date Title
JP4667691B2 (en) Process for the preparation of nitroxyalkyl esters of naproxen
KR20240135777A (en) Method for synthesizing high-purity plant-derived cholesterol
JPS6240358B2 (en)
CN102827064B (en) A kind of synthetic method of azabicyclo[3.3.0]octane derivative
KR20240135778A (en) Synthesis method of high purity cholesterol
WO1999058513A1 (en) Novel intermediates and processes for the preparation of optically active octanoic acid derivatives
CN108623456A (en) The preparation method of butylphenyl phthaleine and its pharmaceutical intermediate
CN102827063B (en) Synthetic method for aza-bicyclo octane[3.3.0] derivatives
WO2016078505A1 (en) Preparation method of fluorene ethyl ketone derivative
CN102643194B (en) Preparation method of posaconazole intermediate
Meshram et al. Bismuthtriflate-catalyzed Reaction of N-Alkylisatins with Allyltrimethylsilane
CN107629064A (en) A kind of synthetic method of Azacyclooctane and Furanones compound
CN102718695B (en) Method for synthesizing aza-bicyclo octane [3.3.0] derivatives
CN102127038B (en) Method for synthetizing mono-thioether compound
CN102807501A (en) Non-natural chiral amino acid and biological catalysis desymmetrisation preparation method thereof
CN102838609B (en) Azabicyclo [3.3.0] octane derivative, as well as preparation method and application thereof
CN109134351B (en) The synthetic method of S-3-(4-aminophenyl) piperidine
CN107721917B (en) A kind of green synthesis method of polysubstituted nicotinic acid ester compounds
CN114805289B (en) Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound
CN116640064B (en) A kind of synthetic method of 4'-chloro-2-aminobiphenyl
CN103864679B (en) A kind of preparation method of 3-methyl-2-pyridine carboxylic acid methyl esters
CN101215292A (en) Synthetic method of dibenzyl biotin and its derivatives
JP2011057575A (en) Manufacturing method of 4-hydroxybenzothiophene derivative
CN116082386A (en) A kind of synthetic method containing ester group lipid
CN102816105A (en) Azabicyclo[4.3.0]nonenoyl halide intermediate, its preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140402

Termination date: 20210625